Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A synthetic non-phosphopeptide derived from human EPHB1/2 around the phosphorylation site of tyrosine594/604 (K-I-YP-I-D)|
|Purification||Antigen affinity chromatography|
|Storage buffer||Dulbecco's PBS, pH 7.4, with 150mM NaCl, 50% glycerol|
|Contains||0.02% sodium azide|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:100|
|Western Blot (WB)||1:500-1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
The Eph subfamily represents the largest group of receptor protein tyrosine kinases identified to date. While the biological activities of these receptors have yet to be determined, there is increasing evidence that they are involved in central nervous system function and in development. The Eph subfamily receptors of human origin (and their murine/avian homologs) include EphA1(Eph), EphA2 (Eck), EphA3 (Hek4), EphA4 (Hek8), EphA5 (Hek7), EphA6 (Hek12),EphA7 (Hek11/MDK1), EphA8 (Hek3), EphB1 (Hek6), EphB2 (Hek5), EphB3(Cek10, Hek2), EphB4 (Htk), EphB5 (Hek9) and EphB6 (Mep). Ligands for Eph receptors include ephrin-A4 (LERK-4) which binds EphA3 and EphB1. In addition, Ephrin-A2 (Elf-1) has been described as the ligand for EphA4, ephrin-A3 (Ehk1-L) as the ligand for EphA5 and ephrin-B2 (Htk-L) as the ligand for EphB4 (Htk).
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
CAPB; developmentally-regulated Eph-related tyrosine kinase; EK6; ELK-related protein tyrosine kinase; elk-related tyrosine kinase; Eph receptor B2 (ELK-related protein tyrosine kinase); eph tyrosine kinase 2; eph tyrosine kinase 3; EPH-like kinase 5; EPH-like kinase 6; EPHB2, Ephrin type-B receptor 1; EPHB3, DRT; ephrin type-B receptor 1; ephrin type-B receptor 2; EPHT3; ERK; ETK2; HEK2; Hek5; MGC87492; NET, HEK-6, ELK, Ephrin type-B receptor 2, Ephrin B1, EphrinB1, Ephrin B2, EphrinB2; neural kinase; neuronally-expressed EPH-related tyrosine kinase; nuk receptor tyrosine kinase; PCBC; protein-tyrosine kinase HEK5; renal carcinoma antigen NY-REN-47; soluble EPHB1 variant 1; Tyro5; TYRO6; tyrosine-protein kinase receptor EPH-2; tyrosine-protein kinase receptor EPH-3; tyrosine-protein kinase receptor SEK-3; tyrosine-protein kinase TYRO5
9330129L11; AW488255; C130099E04Rik; CAPB; Cek5; Cek6; DRT; EK5; ELK; Elkh; ENSMUSG00000074119; EPHB1; EPHB2; EPHT2; EPHT3; Epth2; EPTH3; ERK; ETECK; HEK5; HEK6; NET; Nuk; PCBC; Prkm5; Qek5; Sek3; TYRO5